Prostate Cancer Radiotherapy Outcomes Studied
New findings examine survival rates for men with positive pelvic lymph nodes receiving targeted radiation therapy.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Do you trust that new multi-modal therapies significantly improve long-term cancer outcomes?
A retrospective study of 1,166 men explored how elective pelvic lymph node radiotherapy affects treatment outcomes for advanced prostate cancer. The research provides updated insights for patients considering radiation as part of their broader care plan.
Why it matters
Researchers investigated outcomes for this population because data for men with specific patterns of disease spread, such as mesorectal or oligometastatic bony disease, remains limited. These findings help clarify how different disease classifications influence long-term progression risks.
In a retrospective study of 1,166 men followed for a median of 29 months, researchers evaluated outcomes for patients treated with elective pelvic nodal radiotherapy. Results indicated that M1b disease was associated with higher risks of biochemical and distant progression than M1a disease.
The players
Jade Dodge
A researcher who presented this study on elective pelvic nodal radiotherapy for prostate cancer.
ASTRO
The American Society for Radiation Oncology, which facilitates research and best practices for cancer radiation therapy.
The details
Researchers utilized Kaplan-Meier analysis and multivariable Cox-proportional hazard models to assess how clinicodemographic variables influence survival. Patients in the cohort received elective pelvic lymph node radiotherapy doses of 45-46.8 Gy, combined with systemic therapies including androgen deprivation therapy in 94% of cases and androgen receptor pathway inhibitors in 79% of participants. This approach aims to address all visible disease sites to improve patient outcomes.
Timeline
2014-2024: Patients were treated for this retrospective analysis.
September 26-30, 2026: The study was presented at the 68th Annual ASTRO Meeting in Boston.
Health Landscape
This study builds upon the evolving standard of care for prostate cancer patients by providing data on radiotherapy for metastatic disease. It adds to the ongoing scientific discourse presented at the 2026 ASTRO annual meeting regarding treatment optimization for advanced disease stages.
These findings underscore the importance of discussing specific disease classifications with your oncology team to understand individual risk profiles. If you are navigating advanced prostate cancer, ask your physician how your specific staging impacts treatment options and long-term goals.
The takeaway
While overall survival did not differ significantly between M1a and M1b groups, specific patterns of metastatic spread influenced the risk of disease progression. Patients should track their biochemical markers and consult their physician about how their staging informs their radiotherapy plan.
Further reading
For more information on the latest research and standard treatment approaches, visit our Cancer section.
Source note: This article includes information reported by Urotoday.
Live Poll
Do you trust that new multi-modal therapies significantly improve long-term cancer outcomes?
